Wockhardt Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.0 pts more than Nifty Smallcap 250 and 8.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Wockhardt reported a sharp turnaround on a standalone basis in Q2 FY26, with profit after tax of ₹54 crore versus a loss of ₹36 crore in the year-ago quarter, driven by lower total expenses (₹356 cr vs ₹417 cr) and higher other income. Standalone revenue from operations rose modestly to ₹380 crore (₹370 cr YoY). On a consolidated basis, Q2 revenue declined about 6% YoY to ₹762 crore, but the company swung to a profit of ₹82 crore from a loss of ₹16 crore a year earlier. The board approved a ₹97 crore exceptional charge relating to the deconsolidation of its US step-down subsidiaries — Morton Grove Pharmaceuticals Inc and Wockhardt USA LLC — which filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code on July 11, 2025. The board also appointed former SBI Chairman Mr. Om Prakash Bhatt as an Additional Non-Executive Independent Director, to hold office for five years subject to shareholder approval. Operating cash flow turned strongly positive at ₹189 crore (consolidated) versus ₹32 crore in the prior year period.
Short-term: The US generics exit and one-time ₹97 cr exceptional charge have already been absorbed in H1 FY26, while the sharp profit swing on both standalone and consolidated bases is positive for earnings sentiment. Long-term shareholders should note the strategic withdrawal from the loss-making US generics business, the addition of a high-profile independent director, and a meaningful rise in long-term borrowings (consolidated borrowings rose from ₹1,211 cr to ₹1,669 cr versus March 2025), which lifts leverage even as operating cash flows improved.